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tablet or capsule (8.2%). 12% of the T&CM users had experi-
enced at least one (1) side effect presumably related to the
T&CM use. Socio- demographic factors such as gender, age,
level of education, nature of job and illness, demonstrated
signiﬁcant association with the use of T&CM.
Conclusion: The study showed that there is a high preva-
lence of T&CM use by the studied population which involved
various T&CM modalities. Thus this information will be help-
ful for future clinical implications in terms of research and
development, aswell as public education onT&CMuse around
the region.
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Purpose: Approximately one in ﬁve adult Australia used
Chinese medicine. Respiratory disorders are among the com-
mon reasons that people seek Chinese medicine treatment.
This study aimed to systematically collect and analyze the
characteristics of patients, particularly those with respiratory
disorders, presented to a Chinese medicine tertiary teaching
clinic in Australia.
Methods: Patients’ clinical records from 1 January 2010 to
31 December 2011 at the Chinese medicine teaching clinic
of RMIT University, Australia were extracted to a pre-deﬁned
template and were analyzed using SPSS version 21.0.
Results: The mean age of patients was 42. Approxi-
mately two thirds of the patients were female (65.7%) and
Australian-born (66.2%). The most common conditions that
patients sought Chinese medicine treatments were muscu-
loskeletal and pain disorders, emotional disorders, obstetrics
and gynaecological disorders, respiratory disorders and gas-
trointestinal disorders. Detailed information on 1677 clinical
records presented by 261 patients with respiratory disorders
as the primary complaints were further analyzed. The com-
monly presented respiratory disorders included commoncold,
cough, allergic rhinitis, sinus problems and asthma. Com-
mon acupuncture points and Chinese herbal medicine used
to manage respiratory disorders included LI4, SJ5, LU7, GB20
and LU5, and formulations Yin Qiao San and Sang Ju Wan.
Acupuncture was given at almost all visits (97.5%) and was
combined with herbs most of the time (64.0%). Of the patients
presented with respiratory disorders, 15 adverse events were
reported. Twelve events were mild; three were moderate; and
none were considered severe.
Conclusion: This study provided insights on patients’ char-
acteristics and treatment practice in a Chinese medicine
tertiary teaching clinic in Australia. Respiratory conditions
are commonly presented and treated with a combination of
acupuncture and herbs. Chinese medicine appeared to be safe
and well tolerate by patients.
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Purpose: Meta-analysis (MA) on Chinese herbal medicine
(CHM) trials is increasingly published and indexed in
major international databases but their trustworthiness
and clinical applicability is uncertain. We aimed to assess
the characteristics and methodological quality of MA on
CHM.
Methods: Cross-sectional study. MA published during
1993–2013 was sampled from MEDLINE, EMBASE, Cochrane
Database of Systematic Reviews and Database of Abstracts
of Reviews of Effect. Bibliographical characteristics were
abstracted and methodological quality was assessed
using the validated AMSTAR tool by two independent
reviewers.
Results: Total of 201 MA were included and half were
published in or after 2009. Only 7.5% being updates of previ-
ous reviews. Majority are published in journals with low or
no impact factor, with a median of 1.5. These MA demon-
strated methodological strengths in ensuring comprehensive
literature search, providing characteristics of the included
studies, assessing the scientiﬁc quality of included studies
and appropriately using the scientiﬁc quality of included stud-
ies in formulating conclusions. Nevertheless, weaknesses in
protocol provision, listing of included and excluded studies,
inclusion of grey literature, use of appropriate meta-analytic
technique as well as reporting of funding sources were
prevalent. CHM and control interventions pooled in majority
of MA are found to have substantial clinical heterogene-
ity in terms of composition, dosage form and route of
administration.
Conclusion: There are rooms for improvement in method-
ological rigor, and in choosing clinically homogenous
interventions and control for statistical pooling. These
shortcomings limit the trustworthiness and clinical appli-
cability of existing MA on CHM trials. To overcome
the limitations of pair-wise meta-analysis in synthesizing
trials comparing different CHM and control interven-
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tions, the potential of network meta-analysis should be
explored.
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Purpose: In traditional Chinese medicine (TCM) practice,
decision on prescription is based on a process called Bian
Zheng Lun Zhi (syndrome differentiation guided treatment
decision). The syndrome differentiation process may not
be recognized in conventional standards of randomized
controlled trial (RCT), limiting the model validity and general-
izability of results.
Methods: This article discussed how syndrome differ-
entiation, a classical TCM approach in diagnosis, can be
incorporated into RCT design.
Results: Four methodological solutions were proposed: (i)
Lesson learnt from the design of patient reported outcome
questionnaire can inform how TCM diagnosis instrument
could be developed. A proper TCM diagnostic tool with sound
psychometric properties can reduce variation in the syndrome
differentiation process. (ii) Treatment strategies for a speciﬁc
TCM diagnosis could be highly diversiﬁed. Delphi technique
can inform the design of optimal treatment program by facil-
itating consensus among experts. (iii) Subgroup analysis is
often needed in RCT recruiting patient with several TCM
diagnosis. It is highlighted that investigators should consider
whether the design, analysis and context of the trial are robust
enough to support a reliable claim of subgroup effect associ-
ated with a particular TCM diagnosis. (iv) Finally, we discussed
alternative research and analysis approaches for handling
misalignment of Western and TCM diagnoses, including the
possibility of unifying TCM syndrome with Western pheno-
types using latent class analysis.
Conclusion: Further methodological advances are needed
in the better alignment of classical TCM theories and diagnos-
tic instrument development, as well as in reducing bias during
the expert consensus processes.
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Purpose: Chinese herbal medicine (CHM) has been increas-
ingly used as an adjuvant treatment for multi-drug resistant
tuberculosis (MDR-TB) in China. To inform clinical practice,
we performed a systematic review on the beneﬁcial effect and
safety of CHM for MDR-TB.
Methods: We systematically searched the six electronic
databases for randomised clinical trials (RCTs) of CHM plus
chemotherapy for MDR-TB. RevMan 5.2 software was used for
data analyseswith effect estimates presented as risk ratio (RR)
with 95% conﬁdence interval (CI).
Results: 28 RCTs involving 3085 participants with MDR-
TB were included. The methodological quality was generally
poor in terms of risk of bias. Meta-analyses favoured CHM
plus chemotherapy on sputum bacteriological conversion rate
compared with chemotherapy alone after initiation of treat-
ment (6th months: RR 1.29, 95% CI 1.14 to 1.46, n=11; 12th
months: RR 1.38, 95%CI 1.19 to 1.59, n=5; 18thmonths: RR 1.19,
95% CI 1.11 to 1.28, n=7). Compared with chemotherapy alone,
meta-analysis showed beneﬁt from CHM plus chemotherapy
on lung lesions absorption rate (12th months: RR 1.26, 95% CI
1.09 to 1.46, n=3; 18th months: RR 1.18, 95%CI 1.07 to 1.30, n=6)
andpulmonary cavity closure rate by radiological examination
(18th months: RR 1.24, 95%CI 1.01 to 1.51; n=4), relapse rate (RR
0.28, 95%CI 0.16 to 0.50, n=4), and abnormal liver function (RR
0.56, 95% CI 0.46 to 0.69, n=14).
Conclusion: CHM as an adjuvant to anti-TB chemotherapy
may have beneﬁcial effect for MDR-TB in terms of bacteriolog-
ical and radiological outcomes, and is safe. However, due to
poor methodology of the included trials, a conﬁrmative con-
clusion needs to be supported through further robust clinical
trial.
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